0      0

JL1103EH - JL1103EH: Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma and Prior B-Cell Maturation Antigen (BCMA)-Directed Therapies: A Pooled Analysis From MagnetisMM Studies

Full author listing

Salomon Manier, MD1, Alexander M Lesokhin MD2, Mohamad Mohty MD3, Ruben Niesvizky MD4, Christopher Maisel MD5, Bertrand Arnulf MD6, Sarah M Larson MD7, Asya Nina Varshavsky-Yanovsky MD, PhD8, Xavier Leleu MD9, Lionel Karlin MD10, David H Vesole MD, PhD11, Nizar J Bahlis, MD12, Carlos Fernández de Larrea MD13, Noopur Raje MD14, Eric Leip PhD15, Sharon Sullivan15, Mohamed Elmeliegy PhD16, Andrea Viqueira MD17, Ajay K Nooka MD18

1Lille University Hospital, Lille, France; 2Division of Hematology and Oncology, Memorial Sloan Kettering Cancer Center/Weill Cornell Medical College, New York, NY, USA; 3Sorbonne University, Hôpital Saint-Antoine, and INSERM UMRs938, Paris, France; 4Weill Cornell Medical College - New York Presbyterian Hospital, New York, NY, USA; 5Baylor University Medical Center, Dallas, Tx, USA; 6Hôpital Saint-Louis, Paris, France; 7University of California Los Angeles Medical Center, Los Angeles, CA, USA; 8Fox Chase Cancer Center, Philadelphia, PA, USA; 9Centre Hospitalier Universitaire de Poitiers, Poitiers, France; 10Centre Hospitalier Lyon, Lyon, France; 11John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, USA; 12Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada; 13Hospital Clinic de Barcelona, Barcelona, Spain; 14Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA; 15Pfizer Inc, Cambridge, MA, USA; 16Pfizer Inc, San Diego, CA, USA; 17Pfizer SLU, Madrid, Spain; 18Winship Cancer Institute, Atlanta, GA, USA